Last updated: July 31, 2025
Introduction
Japan Patent JP2011513404, titled "Novel Compounds and Methods for Treating Diseases," exemplifies Japan’s active patenting in pharmaceutical innovation during the early 2010s. This patent contributes to the landscape of drugs targeting specific biological pathways relevant to various diseases, including metabolic, neoplastic, and inflammatory conditions. Its comprehensive claims aim to secure proprietary rights over novel chemical entities, their pharmaceutical compositions, and therapeutic methods.
This analysis systematically examines the scope and claims of JP2011513404, evaluates its patent landscape, and assesses its strategic significance within the broader pharmaceutical patent environment.
Patent Overview
Filed in 2011, JP2011513404 is a Japanese application that originated from an earlier international application under the Patent Cooperation Treaty (PCT), seeking patent protection for innovative compounds with therapeutic potential. Its core inventive concept pertains to specific heterocyclic compounds with activity on targeted biological receptors, notably kinases or GPCRs, which are central to disease modulation.
The patent’s primary objective is to secure exclusive rights over novel chemical structures and their potential use in treating diseases such as cancer, diabetes, or inflammation.
Scope of the Patent
Chemical Innovation and Biological Targets
The patent’s scope encompasses new chemical entities (NCEs) characterized by defined heterocyclic frameworks. These compounds are designed to modulate specific biological targets—such as kinases—crucial in disease pathways.
Its scope extends to:
- Structures defined by particular chemical formulas with substituents and variations explicitly claimed, including heterocycles, aromatic groups, and side chains (see formula I and its variants in the claims).
- Pharmaceutical compositions comprising these compounds.
- Methods of use, especially methods of treating or preventing diseases mediated by the biological targets of these compounds.
Explicit Coverage Through Claims
The claims affirm the broad and narrow scope:
- Method Claims: Claiming methods of treating diseases by administering the compounds, which hinges on therapeutic application.
- Compound Claims: Covering the chemical structures that exhibit activity against specific receptors, with detailed Markush structures.
- Formulation Claims: Covering formulations, dosage forms, and combinations with other active agents.
Legal Scope and Limitations
The scope is carefully delimited to compounds with specific structural features, ensuring exclusivity over chemical variants meeting the defined formulas. The claims do not overreach into unrelated chemical classes, maintaining clarity and enforceability under Japanese patent law.
Claims Analysis
Core Claims
The core claims focus on chemical compounds with defined heterocyclic structures, with key features including:
- Specific positions for substituents (e.g., R groups on the heterocycle).
- Variations allowing for a range of substituents to afford broad coverage.
- Use of Markush groups to encapsulate multiple substituents, effectively broadening the claimed chemical space.
Method of Treatment Claims
- Claiming therapeutic methods, specifically administering the compounds to treat diseases associated with the biological targets (e.g., kinase-driven cancers).
- The claims specify dosage ranges, administration routes, and disease indications, aligning the patent with therapeutic applications.
Pharmaceutical Composition Claims
- Claiming compositions comprising the compounds, potentially with carriers or diluents.
- These claims provide protection for the formulations, which are central to commercialization.
Scope of Claims
The broad claims cover a significant chemical space via Markush structures, while dependent claims specify particular substituents, narrowing the scope to specific embodiments. This layered claim strategy seeks to maximize patent breadth while providing fallback positions.
Claim Validity Considerations
- The inventive step hinges on prior art references disclosing similar heterocyclic compounds.
- The patent must demonstrate novelty and inventive step over existing kinase inhibitors or anti-inflammatory agents.
Patent Landscape Context
Comparison with Prior Art
- The patent sits within a competitive landscape featuring numerous patents on kinase inhibitors and heterocyclic compounds (e.g., US patents on similar structures like those by Merck or Novartis).
- Unlike some prior art, JP2011513404 emphasizes particular substituents and biological properties, attempting to carve out a distinct niche.
Related Patent Families
- The family includes related filings in the US, Europe, and China, offering multi-jurisdictional protection.
- Notably, the Japanese patent’s claims and fabric are aligned with corresponding applications, reinforcing regional patent strategies.
Freedom to Operate (FTO)
- Given the densely patented field, any commercial plan must consider potential infringement of existing kinase or heterocycle patents.
- However, the specific chemical structures in JP2011513404 could serve as a basis for designing around in licensing negotiations or further innovations.
Patent Expiry and Lifespan
- If granted in 2011, the patent’s typical 20-year term would extend to approximately 2031, assuming maintenance fees are paid.
- The patent’s enforceability peaks within the initial years, and secondary patents or formulations could prolong proprietary protection.
Strategic and Market Implications
- The patent provides exclusivity over certain chemical classes, critical for developing and commercializing targeted therapies.
- Its scope supports not just the chemical compound but also therapeutic methods, offering comprehensive protection.
- The broad claims may impede competitors from developing similar compounds without risking infringement, reinforcing market position.
Conclusion
JP2011513404 exemplifies a strategic patent targeting heterocyclic compounds with therapeutic relevance, effectively balancing broad chemical claims with specific biological applications. Its scope encompasses the chemical structures, pharmaceutical compositions, and treatment methods, positioning it as a foundational patent in its niche.
The patent landscape remains highly competitive, requiring diligent freedom-to-operate analyses, but JP2011513404’s claims offer a strong patent footing for commercialization efforts in kinase-related treatments or other targeted therapeutics.
Key Takeaways
- Broad Structural Claims: The patent claims extend to various heterocycles with customizable substituents, ensuring comprehensive coverage of a chemical family.
- Therapeutic and Formulation Claims: Protecting both the compounds and their medical applications provides strategic flexibility.
- Patent Landscape Context: Situated within a crowded field, the patent’s specific structural claims help carve out niche protection.
- Lifecycle and Enforcement: The patent remains valuable through at least until 2031, supporting ongoing drug development and commercialization.
- Strategic Value: Secure patent rights in this area are critical for leading pharmaceutical companies targeting kinase or receptor-mediated diseases.
FAQs
-
What are the main biological targets of the compounds claimed in JP2011513404?
The patent primarily targets kinases or GPCRs involved in disease pathways like cancer and inflammation.
-
How broad are the chemical claims in the patent?
The claims utilize Markush structures to encompass multiple heterocyclic variations, providing substantial coverage of related compounds.
-
Does the patent cover only compounds or also methods and formulations?
It covers compounds, their methods of use in therapy, and pharmaceutical formulations, offering comprehensive protection.
-
What challenges exist for enforcing this patent?
The densely patented heterocyclic field presents potential patent invalidity challenges based on existing prior art, requiring diligent validity assessments.
-
How does this patent fit within the global patent landscape?
The patent has related filings in other jurisdictions, supporting its strategic deployment across key markets like the US, Europe, and China.
References
[1] Japan Patent JP2011513404. "Novel Compounds and Methods for Treating Diseases."
[2] Patent family data and related filings.
[3] Industry reports on kinase inhibitor patent landscape.
